Category: 115619-01-7

115619-01-7, 4-(4-Ethylpiperazin-1-yl)phenylamine is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

mixture of 6-chloro-pyrimidin-4-yl)-amine (500 mg, 3.87 mmol, 1.3 eq.) and 4-(4-ethylpiperazin-1-yl)-aniline (611 mg, 2.98 mmol) in water (3.0 ml) and glacial acetic acid (10ml) is heated to 100C for 15h. The reaction mixture is diluted with DCM and brine. Theaqueous layer is made basic by addition of sodium bicarbonate. The aqueous layer isseparated and extracted with DCM. The organic phase is washed with brine, dried (sodiumsulfate), filtered and concentrated. Purification of the crude product by trituration in EEaffords the title compound: ESI-MS: 299.2 [MHf; tR= 1.05 min (gradient J).

115619-01-7, As the paragraph descriping shows that 115619-01-7 is playing an increasingly important role.

Reference：
Patent; NOVARTIS AG; NOVARTIS PHARMA GMBH; IRM LLC; WO2006/420; (2006); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

115619-01-7, 4-(4-Ethylpiperazin-1-yl)phenylamine is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: The reaction vessel was charged with 5-((3-fluorophenyl)sulfonyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole-3-carboxylic acid(29 mg, 0.16 mmol), diisopropylethylamine (0.035 mL, 0.2 mmol), 1-hydroxybenzotriazole monohydrate (19 mg, 0.12 mmol) and dichloromethane (2 mL) were added and stirred. 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI ?? HCl, 23 mg, 0.12 mmol) was added thereto and stirred at room temperature. The reaction mixture was diluted with dichloromethane (10 mL), water (10 mL) was added, and the mixture was stirred. The organic layer was washed with brine, dried over anhydrous magnesium sulfate and concentrated. The residue was purified by column chromatography (silica gel, dichloromethane: methanol = 30: 1) to obtain the desired compound (50 mg, 90% yield).

115619-01-7, As the paragraph descriping shows that 115619-01-7 is playing an increasingly important role.

Reference£º
Patent; Korea Institute of Science and Technology; Sim Tae-bo; Noh Eun-ju; Yang Han-yong; (33 pag.)KR101936851; (2019); B1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

115619-01-7, 4-(4-Ethylpiperazin-1-yl)phenylamine is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a 0.342 g of 4-(4-ethylpiperazine-1-yl)phenylamine (4d;0.00167 mol) in a dry round bottom flask was added 10 mL 98%ethanol. Then 0.265 g of ethyl 2,4-dioxo-6-methylcyclohexanecarboxylate(E164; previously synthesized in our lab)23 was added. The reactionmixture was refluxed for about 6 h and a total of 5 mL additionalethanol was added. The reaction was monitored by thin layer chromatography(dichloromethane: methanol 85/15). After 6 h, the heatwas turned off and reaction continued to stir at room temperatureovernight. After reaction was completed, the reaction was adsorbed ona silica gel and purified by automated flash chromatography (dichloromethane:methanol 75/25) to yield a yellow semi-solid (54)(0.154 g, 30%).1H NMR (300 MHz, d-CDCl3): delta (ppm) 1.099-1.176 (t,3H), 1.276-1.355 (t, 3H), 1.951 (d, 3H), 2.392-2.547 (q, 2H),2.498-2.641 (t, 4H), 3.211-3.244 (t, 4H), 4.239-4.287 (q, 2H), 5.403(s, 1H), 6.873-6.903 (d, 2H), 7.039-7.069 (d, 2H). HRMS (ESI): m/z,Calcd. for C22H31N3O3 [M+H]+: 386.2433, found 386.2564.

115619-01-7, As the paragraph descriping shows that 115619-01-7 is playing an increasingly important role.

Reference£º
Article; Ghoneim, Ola M.; Bill, Ashley; Dhuguru, Jyothi; Szollosi, Doreen E.; Edafiogho, Ivan O.; Bioorganic and Medicinal Chemistry; vol. 26; 14; (2018); p. 3890 – 3898;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

115619-01-7, 4-(4-Ethylpiperazin-1-yl)phenylamine is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

A mixture of 2,3-dichloro-1,4-naphthoquinone (0.37 g, 1.60 mmol) and 4-(4- methylpiperazin-1-yl)aniline (0.3 g, 1.46 mmol) was dissolved in EtOH (5 ml). The reaction was stirred and refluxed for 16 h. The residue was purified by flash column over silica gel (dichloromethane: methanol= 29: 1) to afford 77 (0.10 g, 17.30 %).1H NMR (300 MHz, CDCl3): delta 1.15 (t, J = 6.0 Hz, 3H), 2.48 (t, J= 6.0 Hz, 2H), 2.63 (t, J= 6.0 Hz, 4H), 3.26 (t, J= 6.0 Hz, 4H), 6.89 (d, J= 9.0 Hz, 2H), 7.03 (d, J= 8.7 Hz, 2H), 7.65-7.70 (m, 2H), 7.77-7.79 (m, 1H), 8.10- 8.13 (m, 1H), 8.18-8.20 (m, 1H).

115619-01-7, 115619-01-7 4-(4-Ethylpiperazin-1-yl)phenylamine 936738, apiperazines compound, is more and more widely used in various fields.

Reference£º
Patent; TAIPEI MEDICAL UNIVERSITY; YEN, Yun; LIOU, Jing-ping; PAN, Shiow-lin; (44 pag.)WO2017/20030; (2017); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.115619-01-7,4-(4-Ethylpiperazin-1-yl)phenylamine,as a common compound, the synthetic route is as follows.

Step 3.Synthesis of 4-(4-ethylpiperazinyl)benzeneisothiocyanate To 4-(4-ethylpiperazinyl)phenylamine in acetone at 0 C. was added sodium bicarbonate (2 eq) and thiophosgene (2 eq).The mixture was brought to ambient temperature and concentrated and partitioned between ethyl acetate and water.The organic layer was dried with sodium bicarbonate and sodium sulfate and concentrated to yield 4-(4-ethylpiperazinyl)benzeneisothiocyanate. MS: MH+=247.

115619-01-7, As the paragraph descriping shows that 115619-01-7 is playing an increasingly important role.

Reference£º
Patent; Amiri, Payman; Fantl, Wendy; Levine, Barry Haskell; Poon, Daniel J.; Ramurthy, Savithri; Renhowe, Paul A.; Subramanian, Sharadha; Sung, Leonard; US2004/122237; (2004); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.115619-01-7,4-(4-Ethylpiperazin-1-yl)phenylamine,as a common compound, the synthetic route is as follows.

A mixture of 4-(4-ethylpiperazin-l-yl)-aniline (1 g, 4.88 mmol), (6-chloro- pyrimidin-4-yl)-methyl-amine (1.81 g, 12.68 mmol, 1.3 eq.), and 4N HC1 in dioxane (15 ml) is heated in a sealed tube to 150C for 5h. The reaction mixture is concentrated, diluted with DCM and a saturated aqueous solution of sodium bicarbonate. The aqueous layer is separated and extracted with DCM. The organic phase is washed with brine, dried (sodium sulfate), filtered and concentrated. Purification of the residue by silica gel column chromatography (DCM/MeOH, 93:7) followed by trituration in diethyl ether affords the title compound as a white solid: ESI-MS: 313.2 [MH]+; tR= 1.10 min (gradient J); TLC: Rf = 0.21 (DCM/MeOH, 93:7)., 115619-01-7

The synthetic route of 115619-01-7 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; NOVARTIS AG; BERGHAUSEN, Joerg; KAPA, Prasad, Koteswara; MCKENNA, Joseph; SLADE, Joel; WU, Raeann; DU, Zhengming; WO2011/71821; (2011); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.115619-01-7,4-(4-Ethylpiperazin-1-yl)phenylamine,as a common compound, the synthetic route is as follows.

SIK inhibitor II-1[00389] To a solution of 1-(6-chloropyrimidin-4-yl)-N-(2,6-dimethylphenyl)-1H- imidazol-2-amine (100 mg, 0.33 mmol) and 4-(4- ethylpiperazin-1-yl)aniline (68 mg, 0.33 mmol) in 2-butanol (1 mL) was added trifluoroacetic acid (TFA, 0.1 mL). The resulting mixture was stirred at 120 C for 4 h, concentrated, and diluted with dimethyl sulfoxide (6 mL). The resulting mixture was purified with preparative HPLC to afford 6-(2-((2,6- dimethylphenyl)amino)-1H-imidazol-1-yl)-N-(4-(4- ethylpiperazin-1-yl)phenyl)pyrimidin-4- amine TFA salt (78 mg, 41% yield) as an off-white solid. Rt = 1.93 min;1H NMR (600 MHz; DMSO-d6) 10.71 (br, 1H), 10.02 (s, 1H), 9.97 (br, 1H), 8.54 (s, 1H), 7.65 (s, 1H), 7.48 (d, J = 6.6 Hz, 2H), 7.20 (m, 4H), 7.10 (s, 1H), 7.01 (d, J = 9.0 Hz, 2H), 6.95 (s, 1H), 3.78 (m, 2H), 3.56 (m, 2H), 3.17 (m, 2H), 3.09 (m, 2H), 2.94 (m, 2H), 2.18 (s, 6H), 1.23 (m, 3H) ppm; MS m/z: 469.46 [M+1].

115619-01-7, The synthetic route of 115619-01-7 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; DANA-FARBER CANCER INSTITUTE, INC.; THE BROAD INSTITUTE, INC.; THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL; PRESIDENT AND FELLOWS OF HARVARD COLLEGE; SHAMJI, Alykhan; SUNDBERG, Thomas; GRAY, Nathanael; XAVIER, Ramnik; SCHREIBER, Stuart, L.; CHOI, Hwan, Geun; LIANG, Yanke; (315 pag.)WO2016/23014; (2016); A2;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

115619-01-7, 4-(4-Ethylpiperazin-1-yl)phenylamine is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Example 46; 8-Ethyl-2- { [4-(4-ethylpiperazin- 1 -yl)phenyl] amino } -4-methyl-6-phenylpyrido [2,3 – d]pyrimidm-7(8H)-one[00242] 8-Ethyl-4-methyl-2-(methylsulfonyl)-6-phenylpyrido[2,3-cdpyrimidin-7(8H)- one (275 mg, 0.80 mmol) and 4-(4-ethylpiperazin-l-yl)aniline (197 mg, 1.2 equiv.) were added to dimethyl sulfoxide (5 mL) and the resulting mixture was heated to 100 0C and stirred overnight. After cooling to room temperature, the reaction was partitioned between aqueous and organic layers with ethyl acetate and H2O, organic layer was dried with anhydrous magnesium sulfate, filtered and evaporated, and directly applied to prep-LC to EPO provide the title compound in (210.0 mg, 56 % yield): 1H NMR (400 MHz, CDCl3): delta 7.80(s, IH), 7.62 (d, 2H), 7.60 (d, 2H)5 7.40 (m, 2H), 7.18 (s, 1eta), 6.95 (d, 2H)5 4.50 (q, 2H)5 3.22(m, 4H)5 2.70 (m, 4H)5 2.60 (s, 3H)5 2.50 (m, 2H)5 1.40 (t, 3H)5 1.20 (t, 3H); MS (EI) forC28^2N6O: 469.10 (MH4)., 115619-01-7

The synthetic route of 115619-01-7 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; EXELIXIS, INC.; WO2007/44698; (2007); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

115619-01-7, 4-(4-Ethylpiperazin-1-yl)phenylamine is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a 0.342 g of 4-(4-ethyl-piperazine-1yl)phenylamine (4d;0.00167 mol) in a dry round bottom flask was added 10 mL of 98%ethanol. The mixture was stirred at room temperature till completedissolution. Then 0.350 g of ethyl 2,4-dioxo-6-phenylcyclohexanecarboxylate(E164; previously synthesized in our lab)23 was added.The reaction mixture was refluxed for about 6 h. The reaction wasmonitored by thin layer chromatography (dichloromethane: methanol85/15). After 6 h, the heat was turned off and reaction continued to stirovernight. After reaction was completed, the reaction was adsorbed ona silica gel and purified by automated flash chromatography (dichloromethane:methanol 75/25) to yield a dark orange solid (0.7059 g,94.9%). 1H NMR (300 MHz, d- CDCl3): delta (ppm) 0.992-1.040 (t, 3H),1.115-1.163 (t, 3H), 2.474-2.498 (q, 2H), 2.600-2.633 (t, 4H),3.203-3.237 (t, 4H), 3.237 (d, 1H), 3.622-3.663 (m, 1H), 4.008-4.037(q, 2H), 5.482 (s, 1H), 6.876-6.906 (d, 2H), 7.052-7.082 (d, 2H),7.297-7.326 (m, 5H). HRMS (ESI): m/z, Calcd. for C27H33N3O3[M+H]+: 448.2589, found 448.2635

115619-01-7, 115619-01-7 4-(4-Ethylpiperazin-1-yl)phenylamine 936738, apiperazines compound, is more and more widely used in various fields.

Reference£º
Article; Ghoneim, Ola M.; Bill, Ashley; Dhuguru, Jyothi; Szollosi, Doreen E.; Edafiogho, Ivan O.; Bioorganic and Medicinal Chemistry; vol. 26; 14; (2018); p. 3890 – 3898;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.115619-01-7,4-(4-Ethylpiperazin-1-yl)phenylamine,as a common compound, the synthetic route is as follows.

According to scheme I, to a 250-mL flash were added Compound Ia-1, i.e. 2,6-dichloro-3,5-dimethoxyaniline (10mmol) and AcOH (24ml), and added dropwisely under an ice-bath a solution of sodium nitrite (15mmol) in sulphuric acid (5.8ml) . The mixture was stirred at 25C until the solution became clear. The resulting dark yellow solution was poured into 150ml of an ice-water, and urea (6mmol) was added. The mixture was stirred and filtered. An aqueous solution of potassium iodide (15mmol) was added to the above dark-yellow solution. The mixture was heated at 85C for 2 hours, and cooled to room temperature. NaHSO3 (3.4 mmol) was added, and the mixture was stirred for 10 minutes. The resulting yellow solid was filtered, dried, and separated by column chromatography to produce Compound Ib-1 (8mmol). Compound Ib-1 (4 mmol), and Compound A-1, i.e. 4-piperidinone ethylene ketal (6 mmol) were dissolved in 50ml toluene, and palladium acetate (0.4 mmol), BINAP (0.48 mmol), and cesium carbonate (18 mmol) were added. The mixture was refluxed under the nitrogen protection for 3 days, and separated by column chromatography to produce Compound Ic-1. Compound Ic-1 (2.5 mmol) was dissolved in 10ml THF, and 10% aqueous H2SO4 solution (10ml) was added. The mixture was heated at 60C overnight, and separated by column chromatography to produce Compound Id-1. Compound Id-1 (1.0 mmol) was dissolved in 10ml dioxane, and DMF.DMA (6.0 mmol) and triethylamine (1.0 mmol) were added. The mixture was refluxed under the nitrogen protection for 2 days, and separated by thin layer chromatography to produce Compound Ie-1. Compound B-1, i.e., 1-fluoro-4-nitrobenzene (10 mmol) was dissolved in 20ml DMF, and C-1, i.e., N-ethylpiperazine (11 mmol), and potassium carbonate (30 mmol) were added. The mixture was reacted at 70C overnight. After cooling, the mixture was poured into ice-water, and filtered to produce Compound If-1. Compound If-1 (10 mmol) was dissolved in 20ml methanol or ethanol, and palladium/carbon (1mmol) was added. The mixture was hydrogenated at room temperature for 7 hours. The mixture was separated by column chromatography to produce Compound Ig-1. Compound Ig-1 (2.6 mmol) was dissolved in 10ml dioxane, and cyanoamine (2.73 mmol), and concentrated hydrochloric acid (3.9 mmol) were added. The mixture was stirred under reflux overnight to produce Compound Ih-1. Compound Ie-1 (1mmol) and Compound Ih-1 (1.05mmol) were dissolved in 8ml ethanol, and sodium acetate (2mmol) and triethylamine (1.05mmol) were added. The mixture was stirred under flux for 7 hours, ethanol concentrated, and water and dichloromethane were added. The organic phase was separated, dried over anhydrous sodium sulphate, and separated by thin layer chromatography to produce Compound I-1 (0.1mmol) in a yield of 10%.H1-NMR(deuterated MeOH) : delta8.11(s, 1H), delta7.56(d, 2H), delta6.99(d, 2H), delta6.72(s, 1H), delta4.25(s, 2H), delta3.93(s, 6H), delta3.56(t, 2H), delta3.23(m, 4H), delta2.92(t, 2H), delta2.8(m, 4H), delta2.64(m, 3H), delta1.2(t, 3H). ESI(+)m/z: 543, 115619-01-7

The synthetic route of 115619-01-7 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Shanghai Allist Pharmaceutical and Medical Technology Corporations; KUANG, Rongren; (39 pag.)EP3466948; (2019); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics